News
Novo Nordisk beats on Q1 earnings, cuts 2025 outlook
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback